Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Madrigal Pharmaceuticals ( (MDGL) ).
On April 22, 2026, Madrigal Pharmaceuticals’ board of directors reclassified its three director classes to more evenly distribute membership ahead of the June 17, 2026 annual stockholders meeting, moving directors Julian C. Baker and Daniel J. Brennan into Class I with terms expiring at the 2026 meeting. The directors’ resignations from their prior classes and simultaneous reappointments to Class I were procedural, left committee roles unchanged, and position Baker, Brennan, and James Daly to stand for re-election in 2026, signaling continuity in the company’s governance structure.
The most recent analyst rating on (MDGL) stock is a Buy with a $644.00 price target. To see the full list of analyst forecasts on Madrigal Pharmaceuticals stock, see the MDGL Stock Forecast page.
Spark’s Take on MDGL Stock
According to Spark, TipRanks’ AI Analyst, MDGL is a Neutral.
The score is driven primarily by strong financial momentum (sharp revenue scaling, very high gross margins, and minimal leverage) but held back by continued net losses and negative free cash flow. Technical indicators are weak with the stock below key moving averages and negative MACD, while the earnings call was constructive on growth and market opportunity but highlighted near-term gross-to-net and expense pressures.
To see Spark’s full report on MDGL stock, click here.
More about Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for liver and cardiometabolic diseases. The company operates in the specialty pharmaceuticals sector, targeting serious conditions with significant unmet medical need and a patient population that often requires long-term, chronic treatment.
Average Trading Volume: 360,887
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.75B
Find detailed analytics on MDGL stock on TipRanks’ Stock Analysis page.